Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Doontyme Dec. 5 at 7:19 PM

$KALA Shares Outstanding before news today 8.21M per Yahoo. outstanding immediately after this offering 19,829,725

1 · Reply

Caitlin2025 Dec. 5 at 7:18 PM

$KALA Still in the green - surprisingly - I’m invested now though

0 · Reply

MetalRooster Dec. 5 at 7:14 PM

$KALA retracement bag holders became investors, here I am, emotional trader, will stop posting until I accept to de risk

0 · Reply

LFC4EVER Dec. 5 at 7:03 PM

$KALA B.U.L.L.I.S.H.

0 · Reply

sxrfxxx Dec. 5 at 6:58 PM

$KALA short fee at the moment 192.50

1 · Reply

TheBullishOne007 Dec. 5 at 6:56 PM

$KALA SSR in place with rapidly rising short borrow fees? YOU DONT SAY LOL 🤩🥳🤪 You will start seeing A LOT of upset bears. BE SURE TO MOCK THEM LOL

0 · Reply

RonJeremyTrades Dec. 5 at 6:54 PM

$KALA

0 · Reply

rrc2007 Dec. 5 at 6:52 PM

$KALA

0 · Reply

Mistral2030 Dec. 5 at 6:51 PM

$KALA

0 · Reply

jtsxlr Dec. 5 at 6:51 PM

$HUBC Down 14% for no apparent reason, Yeah I added. $KALA , $DVLT , $BURU , $IXHL

0 · Reply

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 29, 2025, 12:00 PM EDT - 2 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Aug 8, 2025, 8:18 AM EDT - 4 months ago

Kala Bio (KALA) Q2 Loss Widens 15%

Aug 8, 2025, 8:00 AM EDT - 4 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 4 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 5 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 6 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 10 months ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 19, 2023, 7:12 AM EST - 3 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 3 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 12:01 AM EDT - 3 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 10:54 AM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:00 AM EDT - 3 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 2, 2022, 1:25 PM EDT - 3 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 1, 2022, 9:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Doontyme Dec. 5 at 7:19 PM

$KALA Shares Outstanding before news today 8.21M per Yahoo. outstanding immediately after this offering 19,829,725

1 · Reply

Caitlin2025 Dec. 5 at 7:18 PM

$KALA Still in the green - surprisingly - I’m invested now though

0 · Reply

MetalRooster Dec. 5 at 7:14 PM

$KALA retracement bag holders became investors, here I am, emotional trader, will stop posting until I accept to de risk

0 · Reply

LFC4EVER Dec. 5 at 7:03 PM

$KALA B.U.L.L.I.S.H.

0 · Reply

sxrfxxx Dec. 5 at 6:58 PM

$KALA short fee at the moment 192.50

1 · Reply

TheBullishOne007 Dec. 5 at 6:56 PM

$KALA SSR in place with rapidly rising short borrow fees? YOU DONT SAY LOL 🤩🥳🤪 You will start seeing A LOT of upset bears. BE SURE TO MOCK THEM LOL

0 · Reply

RonJeremyTrades Dec. 5 at 6:54 PM

$KALA

0 · Reply

rrc2007 Dec. 5 at 6:52 PM

$KALA

0 · Reply

Mistral2030 Dec. 5 at 6:51 PM

$KALA

0 · Reply

jtsxlr Dec. 5 at 6:51 PM

$HUBC Down 14% for no apparent reason, Yeah I added. $KALA , $DVLT , $BURU , $IXHL

0 · Reply

Harunkaraca Dec. 5 at 6:50 PM

$KALA

0 · Reply

TheBullishOne007 Dec. 5 at 6:41 PM

$KALA They are going to keep going up. I am not wrong. Short fees will skyrocket next week. The place will stink of bears telling us to sell because we know nothing. Dont. Instead, set your sells high and GTC make sure you tell your broker you do not conset to loaning your shares. I got you. 👍

0 · Reply

TheBullishOne007 Dec. 5 at 6:35 PM

$KALA Been more than 20 mins … think i’ll wait for over $2 at least Short fees quickly rising lol not my fucking problem 🤪

1 · Reply

TheBullishOne007 Dec. 5 at 6:33 PM

$KALA SHORT FEES went up again now over 160% 🫣😳🤯 🤣🤣🤣🤣🤣 Get bent, bears. Your annoying ass mouths, time to cover is closing once again. Told you I always win. Now they will start racing to cover the millions of shares short that just dont exist on to cover with You bears fucked yourselves despite multiple nice warnings SET YOUR SELLS HIGH GTC OF COURSE I AM BULLISH

0 · Reply

popo12341 Dec. 5 at 6:31 PM

$KALA 1$ eod ?

1 · Reply

Stokwits Dec. 5 at 6:27 PM

$KALA Looking for 1.10 today or Monday.

1 · Reply

deedeethegenius Dec. 5 at 6:21 PM

$QCLS $KALA $PMCB $CBIO

0 · Reply

cesar5550 Dec. 5 at 6:14 PM

$KALA .

0 · Reply

killer_7 Dec. 5 at 6:13 PM

$KALA yolo

1 · Reply

TheBullishOne007 Dec. 5 at 6:10 PM

$KALA You guys need conviction. There will be clowns like Donnie everywhere telling you how stupid you are for trying. How any company you buy is the wrong one and the wrong time. Ignore the static. If you have conviction behind your actions, nothing can shake you or force you to LOCK IN A LOSS. Thats all they want. For you to lose so they can profit. 🤷‍♂️ Anyway, short fees here are highest in recent months @ 151% They will cover They will have no choice Hold on guys - im still here because i have conviction in this trade GLTA 👍 BULLISH HERE ;)

2 · Reply

race2zero Dec. 5 at 6:06 PM

$KALA you got a second chance!

1 · Reply

Agge11 Dec. 5 at 6:05 PM

$KALA soon boom to moon 🚀🚀🚀💥💥💥

1 · Reply

Market Cap	6.49M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-3.28

Volume	9,845,891
Avg Vol	9,354,746
Day's Range	N/A - N/A
Shares Out	7.02M
Stochastic %K	27%
Beta	-2.50
Analysts	Hold
Price Target	$1.50